Acadia Healthcare stock
ACHCNASDAQAcadia Healthcare Company, Inc., HealthcareISIN US00404A1097
47Score 47 out of 100, Weak
Price and trend
81 / 100
Price history
+117% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 41% above it.
Since April 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 74).
The price is 2.6% below its 52-week high. Largest decline in 20 years: 87% (November 2022 to January 2026).
Chart figures for advanced users
- SMA 50$30.24
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$26.75
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)74
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$11.68
- The lowest closing price of the last twelve months.
- Resistance$38.80
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Acadia Healthcare Company, Inc. belongs to the Medical (Care Facilities) industry (United States) and, with a market value of $3.52B, is number 21 of 56 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $3.31B (up 5% year on year) and a loss of $1.1B.
- For fiscal 2026, analysts expect on average revenue of $3.43B (up 3.5%) and adjusted earnings per share of $1.53 (down 24.4%).
Show more
- MEQIRI Score 47 out of 100 (Weak): rank 417 of 714 in Healthcare, median 53.
- Our model puts fair value at $27.88, with the price 39% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Analysts expect strong earnings growthUp 16.9% a year through 2028 (estimates from 8 analysts).
Weaknesses
- Loss-makingLoss of $1.13B over the last 12 months.Fundamentals 47
- Turned to a lossEarnings per share from $2.15 in 2021 to −$12.16.Growth 30
- Margin fallingOperating margin 11.7%, average of the prior years 17.3% (to 2024).Profitability 21
Its standout strengths are momentum and technical analysis, while growth and profitability hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- high price swings
- price up very strongly over the past year
- weak fundamentals
What lowers it
- price near its 52-week high
- stable momentum
Valuation
Valuation signal
Modestly overvaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $18.59 and expensive above $55.76 (uncertainty very high, based on the price swings of the past year).
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $22.46, at 7.8% it would be $36.05.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 4.5% on the twelve months before. Revenue has grown strongly since 2010, at around 30% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 18%, operating 12%, net −33%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 24 Feb 2027in 104 days
- Last reported
- 4 Nov 2026EPS reported $0.60 (expected $0.46)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $1.530.0%
- Revenue
- $3.43B0.0%
- Earnings per share
- $1.850.0%
- Revenue
- $3.63B0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: −15.8%Guidance updated, with EBITDA raised according to an analyst: revenue $3.4 billion to $3.45 billion, adjusted EBITDA $590 million to $615 million, adjusted EPS $1.45 to $1.60.
“We are updating our guidance ranges based on progress made this year, and our updated full year guidance now reflects revenue in a range of $3.4 billion to $3.45 billion, adjusted EBITDA in a range of $590 million to $615 million, adjusted EPS in a range of $1.45 to $1.60 and operating cash flow in a range of $350 …”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 28 Jul 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Acadia Healthcare
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 47
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Care Facilities)
The next larger and next smaller companies by market value
- LifeStance Health GroupLFST $5.46B57
- Option Care HealthOPCH $4.75B64
- Hims & Hers HealthHIMS $4.68B35
- MedicoverMCOV-B.ST $4.02B62
- Surgery PartnersSGRY $3.49B53
- National HealthCareNHC $3.3B68
- Guardian Pharmacy ServicesGRDN $3.16B77
- Aveanna Healthcare HoldingsAVAH $2.86B63
ETFs that hold Acadia Healthcare
Held by 14 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Ageing Population UCITS ETF2B77 | 0.30% | 0.40% | €807M |
| iShares S&P SmallCap 600 UCITS ETFIUS3 | 0.17% | 0.30% | €2.28B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.12% | 0.30% | €4.22B |
Show 5 more
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.12% | 0.30% | €2.17B |
| Avantis Global Small Cap Value UCITS ETFAVWS | 0.11% | 0.39% | €1.47B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.11% | 0.30% | €185.82M |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.07% | 0.30% | €944.34M |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.07% | 0.35% | €434.1M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 27 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.